Neoreviews
HOME HELP CONTACT US SUBSCRIPTIONS CME ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Take the CME quiz:
 Vol. 8 No. 2, February 2007
Right arrow E-Letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-Letters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wong, R. J.
Right arrow Articles by Stevenson, D. K.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Wong, R. J.
Right arrow Articles by Stevenson, D. K.

NeoReviews Vol.8 No.2 2007 e77
© 2007 American Academy of Pediatrics

Pharmacology Review

Tin Mesoporphyrin for the Prevention of Severe Neonatal Hyperbilirubinemia

Ronald J. Wong, MD*
Vinod K. Bhutani, MD*
Hendrik J. Vreman, MD*
David K. Stevenson, MD*

* Department of Pediatrics, Division of Neonatal and Developmental Medicine, Stanford University School of Medicine, Stanford, Calif

Competitive inhibitors of heme oxygenase (HO) have been studied as interventional agents for neonatal hyperbilirubinemia. Several naturally occurring and synthetic metalloporphyrins have been shown to be potent inhibitors of HO activity and effective in reducing bilirubin concentrations in vitro and in vivo. Targeting HO may aid in preventing hyperbilirubinemia in newborns. Tin mesoporphyrin (SnMP) has emerged as a potential agent for reducing total bilirubin concentrations in preterm newborns. Adverse effects associated with SnMP use include photosensitization (which complicates its use in conjunction with phototherapy), and potential inhibition of several other enzymes that have essential roles in metabolism. Clinical studies of SnMP have shown that it prevents excessive neonatal hyperbilirubinemia and reduces the need for neonatal phototherapy in term and near-term infants. Because further research, specifically safety investigations, are complicated, use of SnMP should be reserved for neonates who are at especially high risk for developing bilirubin-induced neurologic dysfunction or participating in clinical trials.






HOME HELP CONTACT US SUBSCRIPTIONS CME ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2007 by the American Academy of Pediatrics.